Volume : 12, Issue : 11, November – 2025
Title:
LIPOSOME A NOVEL DRUG CARRIER
Authors :
Akshay R. Birgad, Swati M. Kanoje, Dr. Swati P Deshmukh
Abstract :
Liposomes are the most explored nanocarriers used in targeted drug delivery systems. Liposomes are spherical lipid vesicles (usually 50–500 nm in diameter particle size) composed of one or more lipid bilayers, as a result of emulsifying natural or synthetic lipids in an aqueous medium There are many drugs molecule which is having good Pharmacological action but their use are limited due to the Toxicity, they possess.
Such drugs can be brought into use by reducing its toxicity and enhancing its pharmacological Action. Liposome formulation is an appropriate approach to achieve the therapeutic action of such drugs. Liposome Composition has made it more reliable as it is inert and resembles a cellular membrane which makes it an interesting field of research for scientists. A liposome is a good carrier of drugs in the treatment of cancer and it is Gaining popularity in the field of chemotherapy.
Keywords: Liposome, Components, Types, Classification, Methods, Application.
Cite This Article:
Please cite this article in press Akshay R Birgad et al., Liposome A Novel Drug Carrier, Indo Am. J. P. Sci, 2025; 12(11).
REFERENCES:
[1] Bangham, A. D., Horne, R. W., Negative staining of phospholipids and their structural modification by surface-active agents as Observed in the electron microscope, J. Mol. Bio. 1964, 8, 660-710.
[2] Weissmann, G., Sessa, G., Standish, M., Bangham, A. D., Abstracts, J. Clin. Invest. 1965, 44, 1109–1116.
[3] Georgiadis, G., Swain, C. P., Wills, E. J., Tavill, A. S., Drug-
carrier potential of liposomes in cancer chemotherapy. The Lancet.1974, 303, 1313-1316.
[4] Silvander, M., Johnsson, M., Edwards, K., Effects of PEG-lipids on permeability of phosphatidylcholine/cholesterol liposomes in buffer and in human serum. Chem. Phy. Lip. 1998, 97, 15-26.
[5] Klibanov, A. L., Maruyama, K., Torchilin, V. P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS letters. 1990, 268, 235-237.
[6] Kim, C. E., Lim, S. K., Kim, J. S., In vivo antitumor effect of cromolyn in PEGylated liposomes for pancreatic cancer. J.
controlled release. 2012, 157, 190-195.
[7] Mozafari, M. R., Liposomes: an overview of manufacturing techniques. Cell. Mol. Biol. Lett. 2005, 10, 711.
[8] Bangham, A. D., Hill, M. W., Miller, N. G., Liposomes Methods and Protocol, InMethods in membrane biology, Springer, Boston, MA 1974 pp. 1-68
[9] Langer R. Drug delivery. Drugs on target. Science (New York).2001, 293, 58-59.
[10] Lankalapalli, S., Tenneti, V. S., Adama, R., Preparation and evaluation of liposome formulations for poorly soluble drug itraconazole by complexation. Pharm Lett. 2015, 7, 1-7.
[11] Khar, R. K., Vyas, S. P., Ahmad, F. J., Jain, G. K., (2018); Novel Drug Delivery System The theory and practice of Industrial Pharmacy, 4th Edition, Lachman/Lieberman’s; CBS Publisher and distributors pvt. Ltd.; New Delhi, pp. 883-885.
[12] Dua, J. S., Rana, A. C., Bhandari, A.K., Liposome: methods ofpreparation and applications. Int. J. Pharm. Stud. Res. 2012, 3, 14-20.
[13] Himanshu, A., Sitasharan, P., Singhai, A. K., Liposomes as drug carriers. Int. J. Pharm. Life Sci. 2011, 2, 945-951.
[14] Shaheen, S. M., Shakil, Ahmed, F. R., Hossen, M. N., Ahmed, M.,
Amran, M. S., Ul-Islam, M. A., Liposome as a carrier for advanced drug delivery. Pak. J. Biol. Sci. 2006, 9, 1181-1191.
[15] Vyas, S. P., Khar. R. K., Targeted & controlled drug delivery-
Novel carrier system, CBS publishers and distributors, 2008,pp.182-195.
[16] New, R. R. C., Preparation of Liposomes. In: New RRC (Ed), Liposomes: a practical approach, IRL press, Oxford, 1990, pp. 33-104.
[17] Akbarzadeh, A., Rezaei, Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., et al., Liposome: classification, preparation, and applications. Nano. Res. Lett. 2013, 8, 102.
18. New, R.R.C., Preparation of liposomes. In: New, R.R.C.(Ed.), Lipsomes: A practical approach, IRL Press, Oxford,1990, pp. 33 104.
19. Jr. F. Szoka and D. Papahadjopoulos. Proc. Natl. Acad. Sci. USA, (1978) 60:4194-4198.
20. Jain N.K. Controlled and Novel Drug Delivery. CBS Publisher, Page no. 304-326.
21. Kersten, G.F.A., Crommelin, D.J.A., 1995. Liposomes and ISCOMS as Vaccine formulations. Biochim. Biophys. Acta 1241, 117-138.
22. K. Horton. Disertation for degree of Advanced Studies in Chemical Engineering, Universitat Rovira I Virgili, 2003.
23.Remington. The Science and Practice of Pharmacy. Volume I, 21stEdition, B.I Publishers Pvt Ltd, Page no. 314-316.
24. Godbole MD, Mathur VB, Selection of phospholipid and Method of formulation for optimum entrapment and release Of lamivudine from liposome. Journal of Drug Delivery and Therapeutics, 2018; 8(5-s):175-183. https://doi.org/10.22270/jddt.v8i5-s.1935
25. John DF, Yunus AA, Chigbo UJ, Paul US, Ikenna E. Tolnaftate Loaded liposomes-design, and in-vitro evaluation. Universal Journal of Pharmaceutical Research. 2016; 1(2): 48-53.
26. Anwekar H, Patel S, Singhai AK, Liposomes as drug carriers, international journal of Pharmacy and life sciences, July 2011.
27. Dwivedi C, Yadav R, Tiwari SP, Satapathy T, Roy A, Role of Liposomes in novel drug delivery system, Journal of drug Delivery and therapeutics 2014; 4(2):116-129.
28. Priyanka R Kulkarni, Jaydeep D Yadav, Kumar A Vaidya. Liposomes: A Novel Drug Delivery System. International Journal of current Pharmaceutical and Research 2011; 3(2).
29. Yadav Y, Kumar S, Pandey D, Dutta RK, Liposomes for drug Delivery, Journal of Biotechnology and Biomaterials, 2017.
30. Ugochukwu AE, Nnedimkpa OJ, Rita NO. Preparation and Characterization of Tolterodine tartrate proniosomes, Universal Journal of Pharmaceutical Research. 2017; 2(2):22-25.